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spironolactone may have increased the 
effi  cacy of the ACE inhibitor to reduce 
glomerulosclerosis and markers of tubu-
lar and interstitial damage in the study 
of Kramer et al.1 Th erefore, it is of great 
interest that Kramer et al.1 compared 
spironolactone with amiloride in their 
model with chronic adriamycin neph-
ropathy to control for the effects of 
spironolactone on volume and potassium 
status. In their hands, addition of amilo-
ride to the ACE inhibitor did not mimic 
the benefi cial eff ects of spironolactone; 
this clearly indicates that the benefi cial 
eff ect of spironolactone was mediated by 
non-diuretic eff ects of the drug.
Th is is in line with previous work by 
Hamming et al.9 showing that treat-
ment of rats with adriamycin nephrosis 
with an ACE inhibitor during dietary 
sodium restriction had benefi cial eff ects 
on glomerular injury and decreased 
proteinuria but induced tubulointer-
stitial abnormalities and an increase in 
the total medial area of aff erent arteri-
oles. Th ese arterioles stained positive for 
renin. A direct profi brotic role for renin 
has been postulated independent of its 
ability to generate angiotensin.10 Th ese 
data are distressing, as treatment with 
the ACE inhibitor induced renal fi brosis 
in spite of reduction of proteinuria and 
blood pressure, that is, an improvement 
of the established clinical criteria for a 
good response to therapy. In humans, it 
is usually not feasible to monitor renal 
structural damage during therapy.9
Further studies are needed to explore 
the effect of different diuretics on the 
tubulointerstitium and dissect the 
underlying mechanisms by which vol-
ume depletion infl uences the eff ect of 
ACE inhibition on glomerular and tubu-
lointerstitial injury.
Conclusion
Aldosterone blockade reduces blood 
pressure in virtually all patients with 
hypertension, and aldosterone antago-
nists are useful second- or third-line 
antihypertensive drugs. In addition, 
aldosterone blockade in combination 
with an ACE inhibitor or an AT1 antago-
nist reduces glomerular and tubulointer-
stitial injury in models of renal disease, 
as shown by Kramer et al.1 In proteinu-
ric patients, addition of an aldosterone 
antagonist reduces proteinuria. Initial 
encouraging pilot data are available sug-
gesting that this may translate into pres-
ervation of the GFR in the longer term. 
More clinical studies are warranted to 
address more defi nitively the safety and 
the effi  cacy of aldosterone antagonists 
in advanced chronic kidney disease. 
And fi nally, coming back to the observa-
tion by Kramer et al.1 and Hamming et 
al.,9  further work is needed to shed light 
on the precise mechanisms underlying 
eff ects of volume depletion on the tubu-
lointerstitium during ACE inhibition.
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Control of hyperphosphatemia 
beyond phosphate
P Evenepoel1
Hyperphosphatemia is a prevalent condition in the dialysis population 
and is associated with bad outcome. Block et al. present data 
from a post hoc analysis indicating that sevelamer, a noncalcium-
containing phosphate binder , may confer a survival benefit in 
incident hyperphosphatemic hemodialysis patients. This is the first 
intervention study in the field of mineral metabolism showing a 
beneficial effect on a hard end point.  
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Patients with chronic kidney disease 
(CKD) are at increased risk for car-
diovascular morbidity and mortality.1 
At present, the data support excessive 
atherosclerosis in CKD, and atheroscle-
rotic lesions in CKD patients are more 
likely to be severely calcifi ed than those 
in the general population.2 Furthermore, 
there is increasing stiff ening of larger 
elastic arteries in CKD, with increased 
calcification.3 At least in non-uremic 
individuals, both the extent and the pro-
gression of cardiovascular calcifi cation 
have been associated with a substantial 
see original article on page 438
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increase in the risk of cardiovascular 
morbidity and mortality.4 This asso-
ciation is much less substantiated in the 
dialysis population. Baseline data from 
a study by Raggi et al.5 demonstrate that 
previous myocardial infarction, angina, 
and known coronary artery disease are 
all common in dialysis patients with 
higher calcification scores. In a 5- to 
6-year follow-up study, Blacher et al.6 
noted a strong association between the 
presence and severity of vascular calcifi -
cations and all-cause mortality in CKD 
stage 5D patients.6
Various noninvasive methods have been 
developed to detect and measure vascular 
and valvular calcifi cation. Th e two most 
valuable methods are electron-beam com-
puted tomography and multislice/helical 
computed tomography.4,7 Th e availabil-
ity of both techniques has triggered the 
increased awareness of cardiovascular 
calcifi cations in CKD. Important short-
comings of both computed tomography-
based imaging methods are the lack of 
diff erentiation between calcifi cations of 
the vascular intima and media and that 
they cannot be used in patients with 
arrhythmia. Additional disadvantages 
include cost and radiation exposure.7 
Bellasi et al.8 recently demonstrated that 
abdominal aorta calcifi cation on plain X-
ray fi lms may accurately predict signifi -
cant coronary calcifi cation in the dialysis 
population and may thus represent a valid 
alternative in clinical practice.8
Th e pathogenesis of vascular calcifi -
cation in CKD is not well understood 
and, like that in the general population, 
is almost certainly multifactorial.2,9,10 
In CKD patients, several studies have 
found associations of both traditional 
and uremic-specific risk factors with 
calcification. However, these associa-
tions do not prove cause and eff ect, and 
prospective studies in humans or, at a 
minimum, experimental data are needed 
to definitely confirm the role of these 
factors. Although vascular calcifi cation 
has traditionally been considered to be 
a physicochemical ‘passive’ precipita-
tion in the tunica media of vessel walls, 
there are abundant animal and clinical 
data supporting the notion that more 
important than this passive process is 
an active ordered and regulated process. 
As has been elegantly demonstrated by 
Jono et al., high phosphate levels may 
change the phenotype of human aortic 
vascular smooth muscle cells in vitro 
from contractile to secretory in a fashion 
dependent on normal sodium–phosphate 
cotransport leading to upregulation of 
many genes associated with matrix 
mineralization.11 Th e recognition that 
hyperphosphatemia might be the pri-
mary culprit of accelerated calcifi cation 
in CKD has led to a renewed interest in 
optimizing the treatment of hyperphos-
phatemia. Besides dietary restrictions, 
calcium-containing phosphate bind-
ers have been the mainstay to control 
hyperphosphatemia for more than two 
decades. In recent years, non-calcium-
containing phosphate binders have 
become available, such as sevelamer.12 As 
far as the control of hyperphosphatemia 
in dialysis patients is concerned, several 
studies apart from the Calcium Acetate 
Renagel Evaluation (CARE) trial13 have 
demonstrated comparable efficacy of 
sevelamer to calcium acetate.12,14,15 
Despite an equal serum phosphorus con-
trol, sevelamer has been demonstrated 
to attenuate the progression of coronary 
calcifi cation as compared with calcium 
acetate in both prevalent (Treat To Goal 
trial)16 and incident (Renagel in New 
Dialysis trial)17 hemodialysis patients.
Whether cardiovascular calcifi cations 
are an independent predictor of mor-
tality in dialysis patients and whether 
interventions that reduce cardiovascu-
lar calcifi cations lead to an improvement 
in mortality remained open questions 
so far.
To answer these questions, Block et al.18 
(this issue) performed a post hoc survival 
analysis of patients included in the afore-
mentioned RIND trial. Th is study pro-
vides evidence that, as in non-uremics, the 
presence of coronary artery calcifi cation 
in patients with CKD stage 5D is associ-
ated with a worse outcome. Even more 
fascinating is the observation of a signifi -
cant survival benefi t in patients assigned 
to treatment with sevelamer as compared 
with calcium acetate. Th is observation 
contrasts with the fi ndings of the Dialy-
sis Clinical Outcomes Revisited (DCOR) 
study, which failed to show a signifi cant 
diff erence in mortality.19 Th e apparent 
contradiction between the present study 
by Block et al.18 and the DCOR trial may 
be explained at least partly by diff erences 
in case mix (for example, incident versus 
prevalent hemodialysis patients) and dura-
tion of follow-up (44 versus 20 months). 
At present, however, it is too early to 
generally advocate sevelamer as a fi rst-
line phosphate binder. Th e design of the 
study, a post hoc analysis with its inherent 
limitations, the small size and the specifi -
cities of the study cohort (young age, high 
prevalence of diabetes, incident patients) 
necessitate additional investigations for 
confi rmation. Besides effi  cacy, the bud-
getary impact of a medication has also to 
be considered, as health-care resources 
are under continuous pressure. Although 
specifi c data on this point are lacking, it 
is unlikely that at present the reduction 
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Figure 1 | Pleiotropic effects of sevelamer that may contribute to the abolition of progression 
of vascular calcification and/or the survival benefit.
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of expensive cardiovascular complica-
tions by sevelamer will outweigh its over-
all extra cost.20 It is therefore of utmost 
importance to identify subgroups that will 
benefi t most from treatment with sevela-
mer. Th e parent RIND study17 as well as 
this post hoc analysis18 suggests that treat-
ment with sevelamer will be especially of 
benefi t in incident calcifi ed hemodialysis 
patients.
Undoubtedly, the study by Block et 
al.18 will fuel the ongoing controversy 
on the potential role of calcium load-
ing resulting from the use of calcium-
containing phosphate binder in the 
pathogenesis of cardiovascular calcifi ca-
tion.21–23 Th is controversy was initiated 
by observations made by two independ-
ent research groups in the late 1990s.3,24 
Both observed an independent associa-
tion between the extent of vascular cal-
cifi cation and the prescribed daily dose 
of calcium-containing phosphate binder. 
Opposite to the Treat To Goal study,16 
the RIND study17 provides detailed 
information on dialysate calcium con-
tent, vitamin D usage, and nocturnal 
calcium supplements. Calcium dialysate 
was fi xed in all patients at 1.25 mmol, 
only two patients allocated to sevelamer 
were receiving nocturnal calcium supple-
ments, and vitamin D usage was similar 
in both groups. It is therefore most likely 
that the higher serum calcium levels and 
higher prevalence of episodes of hyper-
calcemia in the calcium acetate group are 
due to the extra calcium loading related 
to phosphate binder usage. Th e patho-
physiological role of elevated serum 
calcium levels has been made evident by 
recent in vitro data supporting a model 
whereby elevations of calcium, in addi-
tion to elevating the Ca × PO4 product, 
enhance and accelerate human smooth 
muscle cell mineralization via increased 
sodium-dependent phosphate cotrans-
porter level.25,26
Neither the Treat to Goal study16 nor 
the RIND study,17 including the current 
post hoc analysis,18 can inform us solely 
about the role of calcium ingestion in the 
pathogenesis of cardiovascular calcifi ca-
tion. Th is is because the comparator drugs 
(sevelamer and calcium acetate/carbon-
ate) diff ered not only in their ‘calcium 
loading’ but also in their lipid-lowering 
capacities. Sevelamer, overall, causes a 
35% reduction in low-density lipopro-
tein cholesterol levels.16,17 In the parent 
study,17 the mean cholesterol level signifi -
cantly correlated with change in total cor-
onary artery calcifi cation score. It should 
be stressed, however, that not all studies 
have suggested an important infl uence of 
low-density lipoprotein cholesterol lev-
els on the progression of coronary artery 
calcifi cation. For example, Schmermund 
et al.27 failed to observe a relationship 
between on-treatment low-density lipo-
protein cholesterol levels and the progres-
sion of calcifi ed coronary atherosclerosis 
in non-uremics. Moreover, the results of 
the 4D study, comparing the eff ects of 
atorvastatin versus placebo on cardiovas-
cular outcomes in 1255 type 2 diabetic 
patients on maintenance hemodialysis, 
were essentially negative.28
Besides its well-known lipid-lower-
ing eff ect, sevelamer has been shown to 
reduce infl ammation, serum uric acid 
levels, and oxidative stress, to improve 
bone health, and to increase serum 
fetuin-A levels (Figure 1).29–31 Any or 
all of these alternative mechanisms may 
contribute to the abolition of progres-
sion of vascular calcifi cation and/or the 
survival benefi t. Additional studies are 
required to explore the impact of these 
individual mechanisms. The CARE-
2 trial (ClinicalTrials.gov Identifier: 
NCT00211939) will test the hypothesis 
that if low-density lipoprotein levels 
are lowered to a similar level in calcium 
acetate- and sevelamer-treated patients, 
there will be no diff erence in the pro-
gression of cardiovascular calcifi cation. 
Inclusion in this study has been com-
pleted, and results may be expected in the 
near future. In addition, it is important to 
compare other non-calcium phosphate 
binders (such as lanthanum carbonate or 
ferric chloride) with calcium acetate in 
the same way.
In conclusion, there is convincing evi-
dence that sevelamer attenuates the pro-
gression of cardiovascular calcifi cation, 
a condition with bad prognostic implica-
tions for outcome. Block et al.18 provide 
data supporting this line of reasoning. 
However, considering the limitations of 
the study and the drug-related extra cost, 
additional well-designed and adequately 
powered outcome studies are required 
before sevelamer can be advocated as 
the fi rst option in the treatment of hyper-
phosphatemia in all dialysis patients. Th e 
further elucidation of the underlying 
pathophysiological mechanisms, though 
a challenge for the researcher, is of less 
relevance for the clinician.
ACKNOWLEDGMENTS
The author thanks K. Claes, D. Kuypers, and 
Y. Vanrenterghem for their useful comments 
and advice.
REFERENCES
1. Foley RN, Parfrey PS, Sarnak MJ. Clinical 
epidemiology of cardiovascular disease in chronic 
renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3): 
S112–S119.
2. Moe SM, Chen NX. Pathophysiology of vascular 
calcification in chronic kidney disease. Circ Res 
2004; 95: 560–567.
3. Guerin AP, London GM, Marchais SJ, Metivier F. 
Arterial stiffening and vascular calcifications in 
end-stage renal disease. Nephrol Dial Transplant 
2000; 15: 1014–1021.
4. Raggi P. Role of electron-beam computed 
tomography and nuclear stress testing in 
cardiovascular risk assessment. Am J Cardiol 2005; 
96: 20J–27J.
5. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac 
calcification in adult hemodialysis patients. 
A link between end-stage renal disease and 
cardiovascular disease? J Am Coll Cardiol 2002; 39: 
695–701.
6. Blacher J, Guerin AP, Pannier B et al. Arterial 
calcifications, arterial stiffness, and cardiovascular 
risk in end-stage renal disease. Hypertension 2001; 
38: 938–942.
7. Floege J, Ketteler M. Vascular calcification in 
patients with end-stage renal disease. Nephrol 
Dial Transplant 2004; 19(Suppl 5): V59–V66.
8. Bellasi A, Ferramosca E, Muntner P et al. 
Correlation of simple imaging tests and 
coronary artery calcium measured by computed 
tomography in hemodialysis patients. Kidney Int 
2006; 70: 1623–1628.
9. Shanahan CM. Vascular calcification: a matter of 
damage limitation? Nephrol Dial Transplant 2006; 
21: 1166–1169.
10. Goldsmith D, Ritz E, Covic A. Vascular calcification: 
a stiff challenge for the nephrologist. Does 
preventing bone disease cause arterial disease? 
Kidney Int 2004; 66: 1315–1333.
11. Jono S, McKee MD, Murry CE et al. Phosphate 
regulation of vascular smooth muscle cell 
calcification. Circ Res 2000; 87: E10–E17.
12. Burke SK, Dillon MA, Hemken DE et al. Meta-
analysis of the effect of sevelamer on phosphorus, 
calcium, PTH, and serum lipids in dialysis patients. 
Adv Ren Replace Ther 2003; 10: 133–145.
13. Qunibi WY, Hootkins RE, McDowell LL et 
al. Treatment of hyperphosphatemia in 
hemodialysis patients: the Calcium Acetate 
Renagel Evaluation (CARE Study). Kidney Int 2004; 
65: 1914–1926.
14. Bleyer AJ, Burke SK, Dillon M et al. A comparison 
of the calcium-free phosphate binder 
sevelamer hydrochloride with calcium acetate 
in the treatment of hyperphosphatemia in 
hemodialysis patients. Am J Kidney Dis 1999; 33: 
694–701.
Kidney International (2007) 71       379
commentar y
15. Pieper AK, Haffner D, Hoppe B et al. A randomized 
crossover trial comparing sevelamer with calcium 
acetate in children with CKD. Am J Kidney Dis 
2006; 47: 625–635.
16. Chertow GM, Burke SK, Raggi P. Sevelamer 
attenuates the progression of coronary and 
aortic calcification in hemodialysis patients. 
Kidney Int 2002; 62: 245–252.
17. Block GA, Spiegel DM, Ehrlich J et al. Effects 
of sevelamer and calcium on coronary artery 
calcification in patients new to hemodialysis. 
Kidney Int 2005; 68: 1815–1824.
18. Block GA, Raggi P, Bellasi A et al. Mortality effect 
of coronary calcification and phosphate binder 
choice in incident hemodialysis patients. Kidney 
Int 2007; 71: 438–441.
19. Suki W, Zabaneh R, Cangiano J et al. A 
prospective, randomized trial assessing the 
impact on outcomes of sevelamer in dialysis 
patients. The DCOR trial. Nephrol Dial Transplant 
2006; 21(Suppl 4): 145–146.
20. Manns B, Stevens L, Miskulin D et al. A systematic 
review of sevelamer in ESRD and an analysis of 
its potential economic impact in Canada and the 
United States. Kidney Int 2004; 66: 1239–1247.
21. Coladonato JA, Szczech LA, Friedman EA, Owen 
WF Jr. Does calcium kill ESRD patients—the 
skeptic’s perspective. Nephrol Dial Transplant 
2002; 17: 229–232.
22. Canavese C, Bergamo D, Dib H et al. Calcium on 
trial: beyond a reasonable doubt? Kidney Int 2003; 
63: 381–382.
23. Qunibi WY, Nolan CA, Ayus JC. Cardiovascular 
calcification in patients with end-stage renal 
disease: a century-old phenomenon. Kidney Int 
Suppl 2002; 73–80.
24. Goodman WG, Goldin J, Kuizon BD et al. 
Coronary-artery calcification in young adults 
with end-stage renal disease who are undergoing 
dialysis. N Engl J Med 2000; 342: 1478–1483.
25. Reynolds JL, Joannides AJ, Skepper JN et al. 
Human vascular smooth muscle cells undergo 
vesicle-mediated calcification in response to 
changes in extracellular calcium and phosphate 
concentrations: a potential mechanism for 
accelerated vascular calcification in ESRD. J Am 
Soc Nephrol 2004; 15: 2857–2867.
26. Yang H, Curinga G, Giachelli CM. Elevated 
extracellular calcium levels induce smooth 
muscle cell matrix mineralization in vitro. Kidney 
Int 2004; 66: 2293–2299.
27. Schmermund A, Achenbach S, Budde T et al. 
Effect of intensive versus standard lipid-lowering 
treatment with atorvastatin on the progression 
of calcified coronary atherosclerosis over 12 
months: a multicenter, randomized, double-blind 
trial. Circulation 2006; 113: 427–437.
28. Wanner C, Krane V, Marz W et al. Atorvastatin 
in patients with type 2 diabetes mellitus 
undergoing hemodialysis. N Engl J Med 2005; 
353: 238–248.
29. Ferramosca E, Burke S, Chasan-Taber S et al. 
Potential antiatherogenic and anti-inflammatory 
properties of sevelamer in maintenance 
hemodialysis patients. Am Heart J 2005; 149: 
820–825.
30. Garg JP, Chasan-Taber S, Blair A et al. Effects 
of sevelamer and calcium-based phosphate 
binders on uric acid concentrations in patients 
undergoing hemodialysis: a randomized clinical 
trial. Arthritis Rheum 2005; 52: 290–295.
31. Ferreira A, Frazao JM, Faugere MC et al. Effects 
of sevelamer and calcium carbonate on 
bone mineralisation and turnover in chronic 
maintenance haemodialysis patients. Nephrol 
Dial Transplant 2006; 21(Suppl 4): 293.
The genetic susceptibility to IgA 
nephropathy: A novel functional 
candidate gene for incomplete O-
glycosylation of IgA1
I Narita1, Y Kaneko1, D Kondo1, S Goto1, M Sakatsume1 and F Gejyo1
Incompleteness of O-glycosylation in the IgA1 hinge has been 
implicated as a central mechanism in the development of IgA 
nephropathy. Although underglycosylation was reported to be an 
acquired abnormality, genes for enzymes of O-glycosylation, such as 
C1GALT1, may be responsible for susceptibility to IgA nephropathy.
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IgA nephropathy (IgAN), the most com-
mon form of primary glomerulonephritis 
worldwide, is defi ned as the predominant 
IgA1 deposits in the glomerular mesan-
gium. Although the mechanism of the 
deposition remains uncertain, genetic 
factors are considered to underlie the 
development of IgAN. Several candidate 
gene loci and genes have been reported, 
including IGAN1 at 6q22–23;1 however, 
the pathogenic meaning of these in the 
development of IgAN remains elusive. 
While linkage analysis is arguably the 
most powerful method for identifying a 
locus involving rare, high-risk alleles in 
mendelian diseases, genetic association 
analysis is generally considered another 
eff ective method for identifying genetic 
variants related to common and complex 
diseases, as is the case in IgAN.
During the past decade, several lines of 
evidence have been reported indicating 
that incompleteness of O-glycosylation in 
the IgA1 hinge region may be a plausible 
cause of the IgA1 deposition. O-Glycans 
are found in many glycoproteins, par-
ticularly in secretory glycoproteins. Th e 
common core 1 O-glycan structure Galβ-
1-3GalNAc-R is a precursor for many 
extended mucin-type O-glycan struc-
tures on animal-cell surfaces and secreted 
glycoproteins including IgA1. Th e hinge 
region of human IgA1 possesses multiple 
O-glycans, of which synthesis is initiated 
by the addition of GalNAc to serine or 
threonine residues through the activity 
of UDP-N-acetyl-α-d-galactosamine:
polypeptide N-acetylgalactosaminyltrans-
ferases (pp-GalNAc-Ts), followed by core 
1 synthase 1, also called glycoprotein-N-
acetylgalactosamine 3-β-galactosyltrans-
ferase 1, core 1 β3-Gal-T, or T-synthase 
(C1GALT1) (Figure 1).2,3 Aberrantly glyc-
osylated IgA1 molecules readily self-aggre-
gate and tend to form antigen–antibody 
immune complexes with IgG antibodies 
against epitopes in the IgA1 hinge region, 
favoring the generation of macromolecu-
lar aggregates of polymeric IgA1 and IgA 
immune complexes.4,5 Moreover, IgA1 
defi cient in terminal sialic acid and galac-
tose unit shows increased in vitro adhe-
sion to extracellular matrix components, 
such as fi bronectin, type IV collagen, and 
laminin.5 In addition, circulating immune 
complexes containing aberrantly glyco-
sylated IgA1 aff ect mesangial-cell prolif-
eration in vitro. Th erefore, genes encoding 
enzymes involved in the O-glycosylation 
process of IgA1 hinge peptides are attrac-
tive, reasonable, and functional candidates 
for genetic association study.
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